CORD-PICO  

CORD-19:35349bb1fc9290338907b7d7f104c9db3951163b JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
p2_i0 34-66 Pharmacological denotes Entresto® (Sacubitril/Valsartan)
p1_all0 34-81 Intervention denotes Entresto® (Sacubitril/Valsartan) Versus Placebo
p2_i1 74-81 Control denotes Placebo
p1_all1 85-242 Population denotes Dogs with Preclinical Myxomatous Mitral Valve Disease C02 Trimethylamine-N-Oxide and its Precursors in Dogs with Degenerative Mitral Valve Disease Comparison
p2_i2 266-275 Pharmacological denotes Torsemide
p1_all2 266-290 Intervention denotes Torsemide and Furosemide
p2_i3 280-290 Pharmacological denotes Furosemide
p2_i4 445-497 Physical denotes Multi-Institution Transvenous Pacemaker Implantation
p1_all3 445-555 Intervention denotes Multi-Institution Transvenous Pacemaker Implantation Abstract Angiotensin converting enzyme inhibitors (ACEi)
p2_i5 499-555 Pharmacological denotes Abstract Angiotensin converting enzyme inhibitors (ACEi)
p1_all4 700-776 Intervention denotes Entresto®, a combinational angiotensin-receptor blocker/neprilysin inhibitor
p1_all5 809-818 Outcome denotes mortality
p2_o2 809-818 Mortality denotes mortality
p1_all6 822-855 Population denotes human patients with heart failure
p2_i6 868-877 Pharmacological denotes enalapril
p1_all7 868-878 Intervention denotes enalapril.
p1_all8 899-908 Intervention denotes Entresto®
p1_all9 932-944 Population denotes healthy dogs
p1_all10 1106-1124 Intervention denotes placebo-controlled
p2_i7 1106-1124 Control denotes placebo-controlled
p1_all11 1150-1173 Outcome denotes pharmacodynamic effects
p1_all12 1177-1197 Intervention denotes Entresto® to placebo
p2_i8 1190-1197 Control denotes placebo
p1_all13 1201-1261 Population denotes dogs with preclinical myxomatous mitral valve disease (MMVD)
p2_p0 1211-1254 Condition denotes preclinical myxomatous mitral valve disease
p1_all14 1300-1309 Intervention denotes Entresto®
p1_all15 1313-1490 Population denotes dogs with cardiac disease. Client-owned dogs weighing 4-15 kg with ACVIM Stage B2 MMVD were enrolled. Dogs with clinically significant pulmonary hypertension or systemic disease
p1_all16 1699-1964 Outcome denotes Echocardiography, thoracic radiographs (CXR), Doppler systemic arterial pressure (SAP), complete blood count, serum biochemical profile, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, and urinary aldosterone to creatinine ratio (UAldo:C)
p2_o9 1717-1785 Physical denotes thoracic radiographs (CXR), Doppler systemic arterial pressure (SAP)
p2_o9 1787-1807 Physical denotes complete blood count
p2_o9 1809-1834 Physical denotes serum biochemical profile
p2_o9 1836-1909 Physical denotes plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration
p2_o9 1915-1964 Physical denotes urinary aldosterone to creatinine ratio (UAldo:C)
p2_i9 2084-2091 Control denotes placebo
p1_all17 2084-2126 Intervention denotes placebo group by the attending pharmacist.
p2_o12 2204-2253 Physical denotes Serum renal enzyme and electrolyte concentrations
p1_all18 2204-2261 Outcome denotes Serum renal enzyme and electrolyte concentrations and SAP
p2_o12 2258-2261 Physical denotes SAP
p1_all19 2287-2371 Outcome denotes Echocardiography, CXR, SAP, renal panel, plasma NT-proBNP concentration, and UAldo:C
p2_o13 2315-2358 Physical denotes renal panel, plasma NT-proBNP concentration
p2_p1 2398-2406 Sample-size denotes Thirteen
p1_all20 2398-2427 Population denotes Thirteen dogs were recruited:
p1_all21 2428-2437 Intervention denotes Entresto®
p1_all22 2450-2457 Intervention denotes placebo
p2_i10 2450-2457 Control denotes placebo
p1_all23 2471-2505 Outcome denotes median percent increase in UAldo:C
p2_o15 2471-2530 Physical denotes median percent increase in UAldo:C between Day 0 and Day 30
p1_all24 2640-2690 Outcome denotes median percent decrease of NT-proBNP concentration
p2_o16 2667-2690 Physical denotes NT-proBNP concentration
p1_all25 2811-2863 Outcome denotes echocardiographic, CXR, SAP, or biochemical profiles
p2_o17 2843-2863 Physical denotes biochemical profiles
p1_all26 2910-2924 Outcome denotes adverse events
p2_o18 2910-2924 Adverse-effects denotes adverse events
p1_all27 3001-3010 Intervention denotes Entresto®
p2_i11 3098-3105 Control denotes placebo
p1_all28 3098-3116 Intervention denotes placebo. Entresto®
p1_all29 3195-3210 Outcome denotes adverse effects
p2_o21 3195-3210 Adverse-effects denotes adverse effects
p1_all30 3276-3293 Intervention denotes Entresto® to ACEi
p2_i12 3289-3293 Pharmacological denotes ACEi
p1_all31 3401-3410 Intervention denotes Entresto®
p1_all32 3426-3455 Intervention denotes Trimethylamine N-oxide (TMAO)
p2_i13 3426-3455 Pharmacological denotes Trimethylamine N-oxide (TMAO)
p2_i14 3593-3604 Pharmacological denotes L-carnitine
p2_o24 3606-3670 Physical denotes Elevated plasma concentrations of TMAO, choline, and L-carnitine
p2_i15 3659-3670 Pharmacological denotes L-carnitine
p1_all33 3930-3971 Intervention denotes circulating TMAO, choline, or L-carnitine
p2_i16 3960-3971 Pharmacological denotes L-carnitine
p1_all34 3975-4202 Population denotes dogs with degenerative mitral valve disease (DMVD) compared to healthy controls (Controls). Thirty client-owned dogs were recruited, including 10 dogs with CHF secondary to DMVD, 10 dogs with asymptomatic DMVD, and 10 Controls.
p1_all35 4239-4310 Outcome denotes fasting plasma concentrations of TMAO, choline, and carnitine fractions
p2_o27 4239-4310 Physical denotes fasting plasma concentrations of TMAO, choline, and carnitine fractions
p1_all36 4405-4427 Outcome denotes Trimethylamine N-oxide
p2_i17 4405-4427 Pharmacological denotes Trimethylamine N-oxide
p1_all37 4441-4458 Outcome denotes total L-carnitine
p2_o29 4441-4458 Physical denotes total L-carnitine
p2_i18 4447-4458 Pharmacological denotes L-carnitine
p2_o29 4472-4488 Physical denotes carnitine esters
p1_all38 4472-4546 Outcome denotes carnitine esters, and carnitine esters to free carnitine ratio (E/F ratio)
p2_o29 4494-4546 Physical denotes carnitine esters to free carnitine ratio (E/F ratio)
p1_all39 4621-4643 Outcome denotes Trimethylamine N-oxide
p2_i19 4621-4643 Pharmacological denotes Trimethylamine N-oxide
p2_o30 4621-4643 Physical denotes Trimethylamine N-oxide
p1_all40 4678-4695 Outcome denotes total L-carnitine
p2_o30 4678-4695 Physical denotes total L-carnitine
p2_o30 4709-4725 Physical denotes carnitine esters
p1_all41 4709-4756 Outcome denotes carnitine esters, free carnitine, and E/F ratio
p2_o30 4727-4756 Physical denotes free carnitine, and E/F ratio
p1_all42 4930-4952 Outcome denotes concentrations of TMAO
p2_o32 4930-4952 Physical denotes concentrations of TMAO
p1_all43 5212-5226 Intervention denotes Loop diuretics
p1_all44 5258-5282 Population denotes congestive heart failure
p1_all45 5413-5423 Intervention denotes furosemide
p2_i20 5413-5423 Pharmacological denotes furosemide
p1_all46 5536-5575 Population denotes Six, healthy, middle-aged, male beagles
p2_i21 5603-5662 Pharmacological denotes torsemide (0.1mg/kg PO q12h), furosemide (2.0mg/kg PO q12h)
p1_all47 5603-5674 Intervention denotes torsemide (0.1mg/kg PO q12h), furosemide (2.0mg/kg PO q12h), or placebo
p2_i22 5667-5674 Control denotes placebo
p1_all48 6033-6066 Outcome denotes Twenty-four hour urine production
p1_all49 6165-6173 Outcome denotes diuresis
p2_o39 6165-6173 Physical denotes diuresis
p2_i23 6179-6189 Pharmacological denotes furosemide
p1_all50 6179-6190 Intervention denotes furosemide.
p2_o40 6240-6262 Physical denotes average 3-day diuresis
p1_all51 6240-6263 Outcome denotes average 3-day diuresis.
p1_all52 6327-6375 Outcome denotes 24-hour urinary excretion of Na + , Cl -, or K +
p2_o41 6363-6418 Physical denotes Cl -, or K + , though furosemide caused less kaliuresis
p1_all53 6385-6395 Intervention denotes furosemide
p2_i24 6385-6395 Pharmacological denotes furosemide
p1_all54 6408-6418 Outcome denotes kaliuresis
p2_o42 6435-6446 Physical denotes Serum renin
p1_all55 6435-6525 Outcome denotes Serum renin, angiotensin II, and aldosterone and the urine aldosterone-to-creatinine ratio
p2_o42 6448-6525 Physical denotes angiotensin II, and aldosterone and the urine aldosterone-to-creatinine ratio
p1_all56 6594-6601 Intervention denotes placebo
p2_i25 6594-6601 Control denotes placebo
p1_all57 6701-6734 Outcome denotes Creatinine and BUN concentrations
p2_o44 6701-6734 Physical denotes Creatinine and BUN concentrations
p1_all58 6871-6895 Intervention denotes torsemide and furosemide
p2_i26 6885-6895 Pharmacological denotes furosemide
p1_all59 6916-6932 Outcome denotes RAAS activation.
p1_all60 7077-7111 Intervention denotes Transvenous pacemaker implantation
p2_i27 7077-7111 Surgical denotes Transvenous pacemaker implantation
p2_o48 7280-7294 Mortality denotes survival times
p1_all61 7280-7317 Outcome denotes survival times and complication rates
p1_all62 7341-7357 Intervention denotes transve-Atenolol
p2_i28 7341-7357 Pharmacological denotes transve-Atenolol
p1_all63 7411-7470 Population denotes cats affected with hypertrophic obstructive cardiomyopathy.
p2_p2 7430-7469 Condition denotes hypertrophic obstructive cardiomyopathy
p1_all64 7587-7614 Outcome denotes peak atenolol concentration